Explore

Trendline Trendline
Hyundai Bioscience Reveals XAFTY's Efficacy Against Ebola, Suggesting Immediate Treatment Potential

Hyundai Bioscience Reveals XAFTY's Efficacy Against Ebola, Suggesting Immediate Treatment Potential

Hyundai Bioscience Reveals XAFTY's Efficacy Against Ebola, Suggesting Immediate Treatment Potential
Trendline Trendline
Roche's Licensing Agreement Expands Generic Production of Antiviral Flu Drug

Roche's Licensing Agreement Expands Generic Production of Antiviral Flu Drug

Roche's Licensing Agreement Expands Generic Production of Antiviral Flu Drug
Trendline Trendline
Breakthrough Drug Shows Promise in Reversing Skin Aging and Enhancing Healing

Breakthrough Drug Shows Promise in Reversing Skin Aging and Enhancing Healing

Breakthrough Drug Shows Promise in Reversing Skin Aging and Enhancing Healing
Trendline Trendline
Asthma Drug Montelukast Shows Potential to Enhance Cancer Immunotherapy

Asthma Drug Montelukast Shows Potential to Enhance Cancer Immunotherapy

Asthma Drug Montelukast Shows Potential to Enhance Cancer Immunotherapy
Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Results in Obesity Treatment Trial

Eli Lilly's Retatrutide Shows Promising Results in Obesity Treatment Trial

Eli Lilly's Retatrutide Shows Promising Results in Obesity Treatment Trial
Rapid Read Rapid Read
Discharge Medicines Service Faces Underutilization Despite Potential Benefits

Discharge Medicines Service Faces Underutilization Despite Potential Benefits

The Discharge Medicines Service (DMS) in England, designed to prevent hospital readmissions by ensuring patients understand their medications, is underutilized. Despite its potential, only about 1% of hospital patients are referred to the service. The NHS aims to shift healthcare from hospitals to community settings, but the DMS's success is hindered by inconsistent referrals and a 'postcode lottery' effect. The service has shown promise in reducing readmissions and medication-related harm, but its full potential remains untapped due to variable implementation and lack of integrated digital systems.
Trendline Trendline
Eli Lilly's Retatrutide Shows Significant Weight Loss in Obesity Trial

Eli Lilly's Retatrutide Shows Significant Weight Loss in Obesity Trial

Eli Lilly's Retatrutide Shows Significant Weight Loss in Obesity Trial
Rapid Read Rapid Read
MHRA Considers Legislative Measures to Limit Paracetamol Sales Amid Safety Concerns

MHRA Considers Legislative Measures to Limit Paracetamol Sales Amid Safety Concerns

The Medicines and Healthcare Regulatory Agency (MHRA) is evaluating potential legislative actions to curb the excessive sale of paracetamol, as announced by Health Minister Preet Kaur Gill. This initiative follows a parliamentary inquiry by Pippa Heylings, a Liberal Democrat MP, regarding the regulatory framework for liquid paracetamol products. The MHRA is concerned about the potential misuse of paracetamol for impulsive or intentional overdoses. In 2025, the agency updated its voluntary guidelines to limit the sale of solid paracetamol forms, and many retailers have extended these guidelines to liquid formulations. The MHRA's current exploration of legal measures aims to further mitigate risks while ensuring that patients with legitimate needs maintain access to these medications.
Rapid Read Rapid Read
FDA Accepts Viatris' Application for Fast-Acting Meloxicam to Address Acute Pain

FDA Accepts Viatris' Application for Fast-Acting Meloxicam to Address Acute Pain

The U.S. Food and Drug Administration (FDA) has accepted Viatris Inc.'s New Drug Application for a fast-acting formulation of meloxicam, a non-opioid treatment for moderate-to-severe acute pain. This development marks a significant step towards providing a non-opioid alternative for pain management, addressing a critical public health need in the United States. Acute pain, often resulting from surgery or trauma, affects over 80 million Americans annually and is a major reason for emergency department visits. The new formulation, MR-107A-02, has shown promising results in Phase 3 trials, demonstrating rapid onset and sustained analgesic efficacy, with a notable reduction in opioid usage. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for December 27, 2026, to complete its review.
Rapid Read Rapid Read
Leucovorin Autism Treatment Faces Shortage Amid Surging Demand

Leucovorin Autism Treatment Faces Shortage Amid Surging Demand

A supportive care drug, leucovorin, which may help ease hyperactivity and improve speech and communication in children with autism, has become highly sought after, leading to a shortage. The drug, a reduced form of folate or vitamin B9, gained popularity after being promoted by the Trump administration and featured in a widely viewed news story. A study published in JAMA Network Open reported a 2,000% increase in leucovorin prescriptions over three years. Despite its popularity, leucovorin is not FDA-approved for autism spectrum disorder, although it is approved for cerebral folate deficiency. The increased demand has left doctors struggling to meet patient needs, with some parents resorting to over-the-counter folic acid, which experts warn may not be as effective and could potentially cause harm.
Rapid Read Rapid Read
UK Receives Experimental Drug from Japan to Address Hantavirus Outbreak on Cruise Ship

UK Receives Experimental Drug from Japan to Address Hantavirus Outbreak on Cruise Ship

The United Kingdom has acquired supplies of the antiviral drug favipiravir from Japan to address a hantavirus outbreak linked to the Hondius cruise liner. The UK Health Security Agency confirmed the delivery, which aims to bolster treatment stocks despite the low risk of wider transmission in the UK. The outbreak, involving the Andes virus strain, has resulted in three deaths and eight confirmed cases. Favipiravir, sold under the brand name Avigan by Fujifilm's Toyama Chemical, is not licensed in the UK and is considered experimental for hantavirus treatment. The drug works by inhibiting a key enzyme necessary for viral replication. Current evidence of its efficacy against hantavirus is limited to lab and animal studies, with no strong human trial data. The World Health Organization has stated that the outbreak does not pose a pandemic threat.
Rapid Read Rapid Read
Report Reveals Few Sunscreens Meet Safety Standards Amid Health Concerns

Report Reveals Few Sunscreens Meet Safety Standards Amid Health Concerns

A new report by the Environmental Working Group (EWG) has found that only about 20% of nearly 2,800 sunscreen products analyzed meet safety and effectiveness standards. The report highlights concerns over chemical ingredients such as oxybenzone and homosalate, which have been linked to health risks and environmental damage. Oxybenzone, in particular, is associated with endocrine disruption and has been banned in several locations due to its harmful effects on coral reefs. The EWG recommends mineral-based sunscreens, which are less likely to cause skin irritation and are not absorbed into the bloodstream. The report also emphasizes the importance of using sunscreen in conjunction with other protective measures like clothing and shade.